Transdermal Estrogen in Women With Anorexia Nervosa

Anorexia Nervosa Clinical Trial

Official title: Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa

Status Recruiting

Clinical Trial Summary

Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.

Clinical Trial Description

Anorexia nervosa is a prevalent psychiatric with a lifetime prevalence of up to 2.2%. Among the many medical co-morbidities associated with anorexia nervosa, the most common is significant bone loss, which can persist despite weight recovery. Nearly 90% of women with anorexia nervosa have osteopenia and this low bone mass is associated with an increased fracture risk. Nearly 30% of women with anorexia nervosa report a history of a fracture and a prospective study demonstrated a 7-fold increased risk of fracture in women with anorexia nervosa compared to age-matched controls. Because anorexia nervosa is a chronic disease that can persist despite psychiatric and nutritional counseling, the bone loss and increased fracture risk can persist and lead to lifelong morbidity. Therefore, finding a treatment for bone loss associated with anorexia nervosa is of critical importance.

This 18-month randomized, placebo-controlled study will investigate in women (ages 20 to 45 years old) with anorexia nervosa whether treatment with transdermal estrogen replacement will increase bone mineral density (BMD). ;

Related Conditions & MeSH terms

• Anorexia
• Anorexia Nervosa

• NCT number: NCT03875378
• Study type: Interventional
• Source: University of Pittsburgh
• Contact: Pouneh Fazeli, MD
• Phone: 412-586-9700
• Email: pkfazeli@pitt.edu
• Status: Recruiting
• Phase: Phase 2
• Start date: August 28, 2020
• Completion date: December 31, 2025